Advertisement

Other Compounds in Development

  • John F. Ryley
  • Robert S. Gordee
  • David Loebenberg
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 96)

Abstract

Echinocandin B is a lipopeptide produced by some species of Aspergillus which has activity against Candida albicans; it is, however, somewhat toxic, causing particularly haemolysis. Enzymatic removal of the linoleoyl side chain and chemical replacement with a 4-n-octyloxybenzoyl group have resulted in a compound, cilofungin (LY121019), which retains anti-Candida activity but is considerably less toxic (Debono et al. 1988, 1989; see also Chap. 3).

Keywords

Antifungal Agent Antimicrob Agent Cryptococcal Meningitis Fungicidal Activity Fungal Count 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Barrett-Bee K, Lees J, Pinder P, Campbell J, Newboult L (1988) Biochemical studies with a novel antifungal agent, ICI 195,739. Ann NY Acad Sci 544: 231–244PubMedCrossRefGoogle Scholar
  2. Bechter R, Hamada M, Nakashima T (1988) SDZ 89–485; a systemic antimycotic azole derivative is non-teratogenic in vitro and in vivo. Revista Ibèrica de Micolögia 5(Suppl l):Abst P-149Google Scholar
  3. Black HR, Brier GL, Wolny JD, Dorrbecker SH (1989) Pharmacology and pharmacokinetics of cilofungin. 29th Intersci Conf Antimicrob Agents Chemother, Houston TX, ( Abst 1357 )Google Scholar
  4. Boyle FT, Gilman DJ, Gravestock MB, Wardleworth JM (1988) Synthesis and structure-activity relationships of a novel antifungal agent, ICI 195,739. Ann NY Acad Sci 544: 86–100PubMedCrossRefGoogle Scholar
  5. Bulo AN, Bradley SF, Kauffman CA (1988) Susceptibility of yeast-like fungi to a new antifungal agent, LY 121019. Mycoses 31: 330–333PubMedCrossRefGoogle Scholar
  6. Bulo AN, Bradley SF, Kauffman CA (1989) The effect of cilofungin (LY 121019) in combination with amphotericin B or flucytosine against Candida species. Mycoses 32: 46–52PubMedCrossRefGoogle Scholar
  7. Chapman R, Moody J, Fasching C, Sinn L, Gerding D, Peterson L (1989) In vitro and in vivo activity of cilofungin against clinical isolates of Candida albicans and Candida parapsilosis. 29th Intersci Conf Antimicrob Agents Chemother, Houston (Abst 819 )Google Scholar
  8. Clemons KV, Hanson LH, Perlman AM, Stevens DA (1989) Efficacy of SCH39304 in a systemic model of murine coccidioidomycosis. 29th Intersci Conf Antimicrob Agents Chemother, Houston TX, ( Abst 823 )Google Scholar
  9. Debono M, Abbott BJ, Turner JR, Howard LC, Gordee RS, Hunt AS, Barnhart M, Molloy RM, Willard KE, Fukuda D, Butler TF, Zeckner DJ (1988) Synthesis and evaluation of LY 121019, a member of a series of semisynthetic analogues of the antifungal lipopeptide echinocandin B. Ann NY Acad Sci 544: 152–167CrossRefGoogle Scholar
  10. Debono M, Abbott BJ, Fukuda DS, Barnhart M, Willard KE, Molloy RM, Michel KH, Turner JR, Butler TF, Hunt AH (1989) Synthesis of new analogs of echinocandin B by enzymatic deacylation and chemical reacylation of the echinocandin B peptide: synthesis of the antifungal agent cilofungin (LY 121019). J Antibiot 42: 389–397PubMedGoogle Scholar
  11. Defaveri J, Graybill JR (1989a) Treatment of chromoblastomycosis with antifungal azoles. 29th Intersci Conf Antimicrob Agents Chemother, Houston TX, ( Abst 820 )Google Scholar
  12. Defaveri J, Graybill JR (1989b) SCH39304 in treatment of murine pulmonary aspergillosis. 29th Intersci Conf Antimicrob Agents Chemother, Houston TX, Abst 822Google Scholar
  13. Defaveri J, Sun SH, Graybill JR (1989) Treatment of murine coccidioidal meningitis with SCH39304. 29th Intersci Conf Antimicrob Agents Chemother, Houston TX, Abst 824Google Scholar
  14. Denning DW, Hanson LH, Stevens DA (1989) In vitro activity of saperconazole against Aspergillus sp. 29th Intersci Conf Antimicrob Agents Chemother, Houston TX, Abst 722Google Scholar
  15. Desiderio J, Leonard G, Lamb L, Brutkiewicz R, Hibbard J, Beaudoin B, Kessler RE (1988) Activity of BMY 28567, a novel antifungal agent, against a variety of Candida species in vivo. 28th Intersci Conf Antimicrob Agents Chemother, Los Angeles CA, Abst 1002Google Scholar
  16. Fierer J, Kirkland T, Finley F (1990) Comparison of fluconazole and SDZ89-485 for therapy of experimental murine coccidioidomycosis. Antimicrob Agents Chemother 34: 13–16PubMedGoogle Scholar
  17. Fothergill AW, McGough DA, Rinaldi MG (1989) In vitro activity of BAY R 3783, an investigational antifungal triazole. 29th Intersci Conf Antimicrob Agents Chemother, Houston TX, Abst 725Google Scholar
  18. Gordee RS, Zeckner DJ, Ellis LF, Thakkar AL, Howard LC (1984) In vitro and in vivo anti-Candida activity and toxicology of LY 121019. J Antibiot 37: 1054–1065PubMedGoogle Scholar
  19. Gordee RS, Zeckner DJ, Howard LC, Albora WE, Debono M (1988) Anti-Candida activity and toxicology of LY 121019, a novel semisynthetic polypeptide anti-fungal antibiotic. Ann NY Acad Sci 544: 294–309PubMedCrossRefGoogle Scholar
  20. Grassberger MA, Meingassner JG, Schaub F (1988) Synthesis and structure-activity relationships of SDZ 89–485 and analogues. Revista Ibérica de Micológia 5(Suppl l):Abst P-153Google Scholar
  21. Graybill JR, Ahrens J, Rinaldi M (1988) LY 121019 in murine candidiasis: in vivo and in vitro correlations. 28th Intersci Conf Antimicrob Agents Chemother, Los Angeles CA, ( Abst 1527 )Google Scholar
  22. Hall GS, Myles C, Pratt KJ, Washington JA (1988) Cilofungin (LY 121019), an antifungal agent with specific activity against Candida albicans and Candida tropicalis. Antimicrob Agents Chemother 32: 1331–1335PubMedGoogle Scholar
  23. Hanson LH, Perlman AM, Clemons KV, Stevens DA (1989) Synergy between cilofungin and amphotericin B in a murine model of candidosis. 29th Intersci Conf Antimicrob Agents Chemother, Houston TX, ( Abst 818 )Google Scholar
  24. Hector RF (1988) Evaluation of the azole BAY R 3783 in rodent models of candidiasis and cryptococcosis. Revista Ibérica de Micológia 5(Suppl l):Abst 0–4Google Scholar
  25. Hector RF, Yee E (1990) Evaluation of Bay R 3783 in rodent models of superficial and systemic candidiasis, meningeal cryptococcosis, and pulmonary aspergillosis. Antimicrob Agents Chemother 34: 448–454PubMedGoogle Scholar
  26. Hector RF, Zimmer BL, Pappagianis D (1988) Use of the chitin synthase inhibitor nikkomycin Z in murine models of coccidioidomycosis, blastomycosis, and histoplasmosis. Revista Ibérica de Micológia, vol 5, suppl 1, Abst 0–5Google Scholar
  27. Kan VL, Bennett JER (1988) Efficacies of four antifungal agents in experimental murine sporotrichosis. Antimicrob Agents Chemother 32: 1619–1623PubMedGoogle Scholar
  28. Khardori N, Kalvakuntla L, Wong E, Rosenbaum B, Bodey GP (1989) Comparative activities of cilofungin (Lyl21019) and amphotericin B against disseminated Candida albicans infection in neutropenic mice. 29th Intersci Conf Antimicrob Agents Chemother, Houston TX, Abst 817Google Scholar
  29. Kobayashi GS, Travis SJ, Medoff G (1988) In vitro evaluation of SCH 39304, fluconazole and amphotericin B against 12 clinical isolates of Histoplasma capsulatum and comparison of therapeutic efficacies in treating histoplasmosis in immunocompetent and immunosuppressed mice. 28th Intersci Conf Antimicrob Agents Chemother, Los Angeles CA, Abst 172Google Scholar
  30. Kramer W, Kim H, Symchowicz S, Perentesis G, Affrime M, Lin C (1988) Pharmacokinetics of SCH 39304 in man. 28th Intersci Conf Antimicrob Agents Chemother, Los Angeles CA, Abst 165Google Scholar
  31. Lee JW, Lin C, Loebenberg D, Rubin M, Pizzo PA, Walsh TJ (1989) Pharmacokinetics and tissue penetration of SCH 39304 in granulocytopenic and nongranulocytopenic rabbits. Antimicrob Agents Chemother 33: 1932–1935PubMedGoogle Scholar
  32. Lee J, Ritter W, Lecciones J, Kelly P, Pizzo P, Walsh TJ (1989) Plasma pharmacokinetics of Bay R 3783 and its metabolite, Bay U 3625, in rabbits. 29th Intersci Conf Antimicrob Agents Chemother, Houston TX, Abst 727Google Scholar
  33. Lin C, Kim H, Lapiguera A, Loebenberg D, Miller GH, Symchowicz S (1988) Comparative pharmacokinetics of SCH 39304 and fluconazole in mice, rabbits, S. monkeys and C. monkeys. 28th Intersci Conf Antimicrob Agents Chemother, Los Angeles CA, ( Abst 163 )Google Scholar
  34. Lin C, Kim H, Radwanski E, Affrime M, Symchowicz S (1989) Steady-state pharmacokinetics of SCH 39304 in man. 29th Intersci Conf Antimicrobial Agents Chemother, Houston TX, ( Abst 1359 )Google Scholar
  35. Loebenberg D, Parmegiani R, Cacciapuoti A, Antonacci B, Norris C, Menzel F, Moss EL, Yarosh-Tomaine T, Lin CC, Hare RS, Miller GH (1988a) SCH 39304, a new antifungal agent. I. Oral treatment of systemic infections in mice. 28th Intersci Conf Antimicrob Agents Chemother, Los Angeles CA, ( Abst 167 )Google Scholar
  36. Loebenberg D, Parmegiani R, Cacciapuoti A, Antonacci B, Norris C, Menzel F, Moss EL, Yarosh-Tomaine T, Hare RS, Miller GH (1988b) SCH 39304, a new antifungal agent. II. Oral and topical treatment of vaginal and skin infections. 28th Intersci Conf Antimicrob Agents Chemother, Los Angeles CA, ( Abst 168 )Google Scholar
  37. Loebenberg D, Parmegiani R, Moss EL, Frank D, McHugh M, Yarosh-Tomaine T, Antonacci B, Menzel F, Hare RS, Miller GH (1989) SCH39304, a new antifungal agent. Oral activity in a murine model of pulmonary aspergillosis. 29th Intersci Conf Antimicrob Agents Chemother, Houston TX, ( Abst 821 )Google Scholar
  38. McGough DA, Ayo S, Fothergill AW, Rinaldi MG (1989) Saperconazole, a new investigational antifungal triazole: in vitro activity and measurement by a modified bioassay. 29th Intersci Conf Antimicrob Agents Chemother, Houston TX, ( Abst 723 )Google Scholar
  39. Mclntyre KA, Galgiani JN (1989a) pH and other effects on the antifungal activity of cilofungin (LY 121019). Antimicrob Agents Chemother 33: 731–735Google Scholar
  40. Mclntyre KA, Galgiani JN (1989b) In vitro susceptibilities of yeasts to a new antifungal triazole, SCH 39304: effects of test conditions and relation to in vivo efficacy. Antimicrob Agents Chemother 33: 1095–1100Google Scholar
  41. Meunier F, Lambert C, Van Der Auwera P (1990) In-vitro activity of SCH39304 in comparison with amphotericin B and fluconazole. J Antimicrob Chemother 25: 227–236PubMedCrossRefGoogle Scholar
  42. Morrison CJ, Stevens DA (1988) Effect of LY 121019 on experimental murine candidosis. 28th Intersci Conf Antimicrob Agents Chemother, Los Angeles CA, ( Abst 1530 )Google Scholar
  43. Odds FC (1988) Activity of cilofungin (LY 121019) against Candida species in vitro. J Antimicrob Chemother 22: 891–897PubMedCrossRefGoogle Scholar
  44. Oki T, Saitoh K, Tomatsu K, Tornita K, Konishi M, Kawaguchi H (1988) Novel antifungal antibiotic BMY-28567. Ann NY Acad Sci 544: 184–187PubMedCrossRefGoogle Scholar
  45. Okuda T, Tanio T, Ichise K, Nakajima T (1988) In vivo evaluation of SM-8668, a new orally active triazole antifungal agent. 28th Intersci Conf Antimicrob Agents Chemother, Los Angeles CA, ( Abst 174 )Google Scholar
  46. Padula A, Chambers HF (1989) Evaluation of cilofungin (LY121019) for treatment of experimental Candida albicans endocarditis in rabbits. Antimicrob Agents Chemother 33: 1822–1823PubMedGoogle Scholar
  47. Pappagianis D, Zimmer B, Theodoropoulos G, Hector R (1988a) Evaluation of the azole BAY R 3783 in murine models of coccidioidomycosis, blastomycosis, and histoplasmosis. Revista Ibèrica de Micologia 5(Suppl l):Abst 0–64Google Scholar
  48. Pappagianis D, Zimmer B, Hector RV (1988b) Nikkomycin therapy in experimental coccidioidomycosis, blastomycosis and histoplasmosis. 28th Intersci Conf Antimicrob Agents Chemother, Los Angeles CA, ( Abst 1004 )Google Scholar
  49. Pappagianis D, Zimmer BL, Hector RF (1989) Comparative efficacy of the triazole Bay R 3783 in murine models of deep mycoses. 29th Intersci Conf Antimicrob Agents Chemother, Houston TX, ( Abst 726 )Google Scholar
  50. Perfect JR, Wright KA, Hobbs MM, Durak DT (1989a) Treatment of experimental cryptococcal meningitis and disseminated candidiasis with SCH39304. Antimicrob Agents Chemother 33:1735 –1740Google Scholar
  51. Perfect JR, Hobbs MM, Wright KA, Durak DT (1989b) Treatment of experimental disseminated candidiasis with cilofungin. Antimicrob Agents Chemother 33: 1811–1812PubMedGoogle Scholar
  52. Petranyi G, Meingassner JG, Schaude M (1988) Experimental chemotherapeutic activity of SDZ 87–469, a new allylamine antimycotic. Revista Ibèrica de Micologia 5(Suppl 1): Abst P-150Google Scholar
  53. Pfaller M, Riley J, Koerner T (1989) Effects of cilofungin (LY121019) on carbohydrate and sterol composition of Candida albicans. Eur J Clin Microbiol Infect Dis 8: 1067–1070PubMedCrossRefGoogle Scholar
  54. Pfaller M, Gordee R, Gerarden T, Yu M, Wenzel R (1989) Fungicidal activity of cilofungin (LY 121019) alone and in combination with anticapsin or other antifungal agents. Eur J Clin Microbiol Infect Dis 8: 564–567PubMedCrossRefGoogle Scholar
  55. Picard M, Meshulam T, Sugar AM (1988) In vitro activity of LY 121019 against Candida species and Torulopsis glabrata. Eur J Clin Microbiol Infect Dis 7: 432–433PubMedCrossRefGoogle Scholar
  56. Plempel M, Büchel KH (1988) Antimycotic effects of BAY R 3783 in vitro and on dermatophytoses and opportunistic mycoses of the organs in vivo. Re vista Ibèrica de Micologia 5(Suppl l):Abst 0 - 7Google Scholar
  57. Plempel M, Berg D, Büchel K-H, Ritter W (1988) Experimental antimycotic activity of azole derivatives-experience, knowledge and questions. In: Berg D, Plempel M (eds) Sterol biosynthesis inhibitors. Pharmaceutical and agrochemical aspects. Ellis Horwood, Chichester, pp 349–396Google Scholar
  58. Pope LM, Tanaka K, Cole GT (1988) Efficacy of LY 121019 in clearance of Candida albicans from body organs of persistently colonized, immunocompromised mice. 28th Intersci Conf Antimicrob Agents Chemother, Los Angeles CA, ( Abst 1528 )Google Scholar
  59. Rennie RP, Hellman L (1989) Comparative activity in vitro of cilofungin (LY 121019) with other agents used for treatment of deep-seated Candida infections. Mycoses 32: 145–150PubMedCrossRefGoogle Scholar
  60. Restrepo BI, Ahrens J, Graybill JR (1989) Efficacy of SCH39304 in murine cryptococcosis. Antimicrob Agents Chemother 33: 1242–1246PubMedGoogle Scholar
  61. Rinaldi MG, Allendoerfer R, Defaveri J, Graybill JR (1989) Therapy of experimental murine aspergillosis with a new antifungal triazole, saperconazole: initial investigations. 29th Intersci Conf Antimicrobial Agents Chemother, Houston TX, ( Abst 724 )Google Scholar
  62. Ryder NS (1988) Biochemical mode of action and enantiomeric selectivity of SDZ 89-485. Revista Ibèrica de Micologia 5(Suppl l):Abst P-154Google Scholar
  63. Ryley JF, McGregor S, Wilson RG (1988) Activity of ICI 195,739 - a novel, orally active bistriazole-in rodent models of fungal and protozoal infections. Ann NY Acad Sci 544: 310–328PubMedCrossRefGoogle Scholar
  64. Saji I, Ohashi N, Tamoto K, Tanio T, Okuda T, Atsumi T (1988) Structure-activity relationships of SM-8668, a new orally active triazole antifungal, and related compounds. 28th Intersci Conf Antimicrob Agents Chemother, Los Angeles CA, ( Abst 173 )Google Scholar
  65. Schaude M, Mieth H (1988) In vitro activity of SDZ 89-485, a new orally active triazole antifungal. Revista Ibèrica de Micologia 5(Suppl l):Abst P-152Google Scholar
  66. Schaude M, Petranyi G, Meingassner JG, Ackerbauer H, Mieth H (1988) Biological activity of SDZ 89–485 in animal models. Re vista Ibèrica de Micologia 5(Suppl l):Abst P-151Google Scholar
  67. Schmitt HJ, Bernard EM, Hauser M, Armstrong D (1988) Comparison of antifungal agents in a rat model of pulmonary aspergillosis. 28th Intersci Conf Antimicrob Agents Chemother, Los Angeles CA, ( Abst 171 )Google Scholar
  68. Schuster I, Meingassner JG (1988) SDZ 89–485: a study of interactions with mammalian cytochromes P-450 in vitro and in vivo. Re vista Ibèrica de Micologia 5(Suppl l):Abst P-155Google Scholar
  69. Smith K, Lank K, Cobbs G, Dismukes W (1989) Cilofungin vs amphotericin B therapy of murine candidiasis. 29th Intersci Conf Antimicrob Agents Chemother, Houston TX, ( Abst 816 )Google Scholar
  70. Spitzer ED, Travis SJ, Kobayashi GS (1988) Comparative in vitro activity of LY 121019 and amphotericin B against clinical isolates of Candida species. Eur J Clin Microbiol Infect Dis 7: 80–81PubMedCrossRefGoogle Scholar
  71. Stütz A, Nussbaumer P, Petranyi G (1988) SDZ 87–469: synthesis and structure- activity relationships of a novel allylamine antimycotic. Revista Ibèrica de Micologia 5(Suppl l):Abst P-156Google Scholar
  72. Sugar AM, Picard M, Noble L (1989) Comparison of SCH 39304, fluconazole, and amphotericin B in the treatment of murine pulmonary blastomycosis. 29th Intersci Conf Antimicrob Agents Chemother, Houston TX, ( Abst 825 )Google Scholar
  73. Taft CS, Stark, Selitrennikoff CP (1988) Cilofungin (LY 121019) inhibits Candida albicans (l–3)-ß-D-glucan synthase activity. Antimicrob Agents Chemother 32: 1901–1903PubMedGoogle Scholar
  74. Travis SJ, Medoff G, Kobayashi GS (1989) In vitro susceptibility of a clinical isolate of Histoplasma capsulatum to two triazoles does not correlate with treatment outcome in murine histoplasmosis. 29th Intersci conf Antimicrob Agents Chemother, Houston TX, ( Abst 1157 )Google Scholar
  75. Tsai YH, Kelly WA, Ferraro C, Kessler RE (1988) BMY 28567: therapeutic study in murine cryptocoecal meningitis. 28th Intersci Conf Antimicrob Agents Chemother, Los Angeles CA, ( Abst 1003 )Google Scholar
  76. Tsunakawa M, Nishio M, Ohkuma H, Tsuno T, Konishi M, Naito T, Oki T, Kawaguchi H (1988) A new antifungal antibiotic, BMY-28567. Structure elucidation. 28th Intersci Conf Antimicrob Agents Chemother, Los Angeles CA, ( Abst 1001 )Google Scholar
  77. Tucker RM, Hanson LH, Brummer E, Stevens DA (1989) Activity of ICI 195,739, a new oral triazole, compared with that of ketoconazole in the therapy of experimental murine blastomycosis. Antimicrob Agents Chemother 33: 573–575Google Scholar
  78. Van Cutsem J, Van Gerven F, Janssen PAJ (1988) R66905, a new potent broad- spectrum antifungal with topical, oral and parenteral activity. Revista Ibérica de Micológia, vol 5, suppl 1, Abst 0–2Google Scholar
  79. Van Cutsem J, Van Gerven F, Janssen PAJ (1989a) Oral and parenteral therapy with saperconazole (R 66905) of invasive aspergillosis in normal and immunocompromised animals. Antimicrob Agents Chemother 33: 2063–2068PubMedGoogle Scholar
  80. Van Cutsem J, Van Gerven F, Fransen J, Janssen PAJ (1989b) Treatment of experimental zygomycosis in guinea pigs with azoles and with amphotericin B. Chemotherapy 35: 267–272PubMedCrossRefGoogle Scholar
  81. Walsh TJ, Lee JW, Peter J, Schaufele R, Rubin M, Pizzo PA (1988) SCH 39304 in the treatment of disseminated candidiasis in persistently granulocytopenic and non- granulocytopenic rabbits. 28th Intersci Conf Antimicrob Agents Chemother, Los Angeles CA, Abst 169Google Scholar
  82. Walsh TJ, McCully C, Rinaldi MG, Balis F, Lee J, Pizzo PA, Poplack D (1989) Pharmacokinetics and penetration of SCH 39304 into cerebrospinal fluid of rhesus monkeys. 29th Intersci Conf Antimicrob Agents Chemother, Houston TX, Abst 1361Google Scholar
  83. Wright KA, Perfect JR, Ritter W (1989) The pharmacokinetics and efficacy of BAY R3983 in experimental cryptococcal meningitis. 29th Intersci Conf Antimicrob Agents Chemother, Houston TX, Abst 728Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • John F. Ryley
  • Robert S. Gordee
  • David Loebenberg

There are no affiliations available

Personalised recommendations